495 related articles for article (PubMed ID: 33159444)
1. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
Ruddy KJ; Schaid DJ; Batzler A; Cecchini RS; Partridge AH; Norman A; Fehrenbacher L; Stewart EA; Trabuco E; Ginsburg E; Couch FJ; Fasching PA; Vachon C; Ganz PA
J Natl Cancer Inst; 2021 Aug; 113(8):1105-1108. PubMed ID: 33159444
[TBL] [Abstract][Full Text] [Related]
2. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
3. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
4. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
[TBL] [Abstract][Full Text] [Related]
6. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.
Ruddy KJ; O'Neill A; Miller KD; Schneider BP; Baker E; Sparano JA; Dang C; Northfelt DW; Sledge GW; Partridge AH
Breast Cancer Res Treat; 2014 Apr; 144(3):591-7. PubMed ID: 24584876
[TBL] [Abstract][Full Text] [Related]
7. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
9. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
12. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
13. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
[TBL] [Abstract][Full Text] [Related]
14. Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide.
D'Avila ÂM; Biolchi V; Capp E; Corleta Hv
J Ovarian Res; 2015 Dec; 8():82. PubMed ID: 26667243
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
16. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
Swain SM; Land SR; Ritter MW; Costantino JP; Cecchini RS; Mamounas EP; Wolmark N; Ganz PA
Breast Cancer Res Treat; 2009 Jan; 113(2):315-20. PubMed ID: 18302020
[TBL] [Abstract][Full Text] [Related]
17. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
[TBL] [Abstract][Full Text] [Related]
18. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
19. Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study.
Gupta AA; Lee Chong A; Deveault C; Traubici J; Maloney AM; Knight S; Lorenzo A; Allen L
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):599-603. PubMed ID: 27184535
[TBL] [Abstract][Full Text] [Related]
20. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
